|
|
Inpatient and Outpatient Orderable
Paraneoplastic Autoantibody Evaluation, Serum
Synonyms
|
- LAB10818
- PARANEOPLASTIC EVALUATION
- PARANEOPLASTIC NEUROLOGICAL AUTOIMMUNITY
|
Cerner Name
|
Paraneoplastic Evaluation
|
Clinical Info
|
Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology,
especially those with known risk factors for cancer
Directing a focused search for cancer
Investigating neurological symptoms that appear during, or after, cancer therapy and are not explainable by metastasis
Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
Monitoring the immune response of seropositive patients during cancer therapy
Detecting early evidence of cancer recurrence in previously seropositive patients
|
Specimen Sources
|
Blood, Arterial
Blood, Capillary
Blood, Central Line
Blood, Venous
|
Specimen Types
|
Blood
|
Container
|
Gold Top Tube
|
Collection Instructions
|
Container/Tube: Red top tube or Gold Top Tube
Specimen : 4 mL serum (2 mL min)
Transport Temperature: Refrigerated
Patient Preparation:
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication
or intravenous immunoglobulin treatment.
2. This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically,
because of potential assay interference.
The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the
clearance rate in the individual patient.
Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held
1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
|
Specimen Volume
|
4 mL serum (2 mL min)
|
Transport Instructions
|
Refrigerated
|
Specimen Stability
|
3 days Room Temperature
28 Days Refrigerated or Frozen
|
Methodology
|
Indirect Immunofluorescence Assay (IFA)
Radioimmunoassay (RIA)
Western Blot (WB)
Immunoblot (IB)
Cell-Binding Assay (CBA)
|
Days Performed
|
TAT: 11-18 Days
|
Performing Laboratory
|
Mayo Medical Laboratories
|
CPT
|
83516
86596
86255 x 9
LOINC Code: 43104-9
|
PDM
|
5910633
|
Only Orderable at Locations:
|
Orderable Everywhere
|
Results
|
| Component Name |
Base Name |
Common Name |
External Name |
| AMPHIPHYSIN AB, S |
AMPHIPABS |
AMPHIP AB S |
Amphiphysin Ab, S |
| AGNA-1, S |
AGNA1S |
AGNA 1 S |
AGNA-1, S |
| ANNA-1, S |
ANNA1S |
ANNA 1 S |
ANNA-1, S |
| ANNA-2, S |
ANNA2S |
ANNA 2 S |
ANNA-2, S |
| ANNA-3, S |
ANNA3S |
ANNA 3 S |
ANNA-3, S |
| CRMP-5-IGG WESTERN BLOT |
CR5IGWESBLOT |
CR 5 IGG WES BLOT |
CRMP-5-IgG, S |
| NEURONAL (V-G) K+ CHANNEL AB, S |
VGKCHANAB |
NEURONAL VOLTAGE GATED K CHANNEL AB |
Neuronal (V-G) K+ Channel Ab, S |
| P/Q-TYPE ANTIBODY |
PQTYPEANTI |
P Q TYPE ANTIBODY |
P/Q-Type Calcium Channel Ab |
| PCA-1, S |
PCA1S |
PCA 1 S |
PCA-1, S |
| PCA-2, S |
PCA2S |
PCA 2 S |
PCA-2, S |
| PCA-TR, S |
PCATRS |
PCA TR S |
PCA-Tr, S |
| INTERPRETIVE COMMENTS |
PARANEOPLINT |
INTERPRETIVE COMMENTS |
Interpretive Comments |
| IFA NOTES |
IFANOTES |
IFA NOTES |
IFA Notes |
|
Result Interpretation
|
Test ID
|
Reporting name
|
Methodology*
|
Reference value
|
|
PAINT
|
Interpretive Comments
|
Medical interpretation
|
Not applicable
|
|
AMPHS
|
Amphiphysin Ab, S
|
IFA
|
Negative
|
|
AGN1S
|
Anti-Glial Nuclear Ab, Type 1
|
IFA
|
Negative
|
|
ANN1S
|
Anti-Neuronal Nuclear Ab, Type 1
|
IFA
|
Negative
|
|
ANN2S
|
Anti-Neuronal Nuclear Ab, Type 2
|
IFA
|
Negative
|
|
ANN3S
|
Anti-Neuronal Nuclear Ab, Type 3
|
IFA
|
Negative
|
|
CRMS
|
CRMP-5-IgG, S
|
IFA
|
Negative
|
|
VGKC
|
Neuronal (V-G) K+ Channel Ab, S
|
RIA
|
< or =0.02 nmol/L
|
|
CCPQ
|
P/Q-Type Calcium Channel Ab
|
RIA
|
< or =0.02 nmol/L
|
|
PCABP
|
Purkinje Cell Cytoplasmic Ab Type 1
|
IFA
|
Negative
|
|
PCAB2
|
Purkinje Cell Cytoplasmic Ab Type 2
|
IFA
|
Negative
|
|
PCATR
|
Purkinje Cell Cytoplasmic Ab Type Tr
|
IFA
|
Negative
|
Reflex Tests:
|
Test ID
|
Reporting name
|
Methodology*
|
Reference value
|
|
AGNBS
|
AGNA-1 Immunoblot, S
|
IB
|
Negative
|
|
AGNTS
|
AGNA-1 Titer, S
|
IFA
|
<1:240
|
|
AMIBS
|
Amphiphysin Immunoblot, S
|
IB
|
Negative
|
|
AN1BS
|
ANNA-1 Immunoblot, S
|
IB
|
Negative
|
|
AN1TS
|
ANNA-1 Titer, S
|
IFA
|
<1:240
|
|
AN2BS
|
ANNA-2 Immunoblot, S
|
IB
|
Negative
|
|
AN2TS
|
ANNA-2 Titer, S
|
IFA
|
<1:240
|
|
AN3TS
|
ANNA-3 Titer, S
|
IFA
|
<1:240
|
|
APHTS
|
Amphiphysin Ab Titer, S
|
IFA
|
<1:240
|
|
CRMTS
|
CRMP-5-IgG Titer, S
|
IFA
|
<1:240
|
|
CS2CS
|
CASPR2-IgG CBA, S
|
CBA
|
Negative
|
|
CRMWS
|
CRMP-5-IgG Western Blot, S
|
WB
|
Negative
|
|
LG1CS
|
LGI1-IgG CBA, S
|
CBA
|
Negative
|
|
PC1BS
|
PCA-1 Immunoblot, S
|
IB
|
Negative
|
|
PC1TS
|
PCA-1 Titer, S
|
IFA
|
<1:240
|
|
PC2TS
|
PCA-2 Titer, S
|
IFA
|
<1:240
|
|
PCTBS
|
PCA-Tr Immunoblot, S
|
IB
|
Negative
|
|
PCTTS
|
PCA-Tr Titer, S
|
IFA
|
<1:240
|
|
Forms
|
|
LAB10818
|
